bluebird bio Inc. (BLUE)

Business: bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases.

IPO Date: 19-Jun-2013

Pres, CEO & Director: Mr. Andrew Obenshain

Treasurer, Principal Accounting Officer & Financial Officer and Chief Strategy & Financial Officer: Mr. Jason F. Cole Esq.

Listing: NASDAQ: BLUE

Country: United States

Headquarters: Cambridge, MA

Website: https://www.bluebirdbio.com

Market cap: $327.26 Mln

Revenue (TTM): $-7.19 Mln

Earnings (TTM): $-735.72 Mln

Cash: $211.59 Mln

Total Debt: $110.34 Mln

Insider's Holding: 1.16%

Liquidity: Low

52 Week range: $2.87 - 21.16

Shares outstanding: 71,453,696

10 Years Aggregate:

• CFO: $-2,689.72 Mln
• EBITDA: $-3,501.31 Mln
• Net Profit: $-3,646.94 Mln